KRAS and cancer: 3M‐052 has also been successfully employed in various nanoparticle platforms for cancer and infectious disease immunotherapy, supporting its inclusion in our spleen‐targeted KRAS mRNA lipid nanoparticles designed to drive effective T cell priming and tumor infiltration.[7, 14, 15, 16, 17] The LNPs were synthesized using a microfluidic system.